• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Unicycive Therapeutics, Inc. - Common Stock (NQ:UNCY)

    4.220 -0.330 (-7.25%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,510,068
    Open 4.620
    Bid (Size) 4.200 (1,000)
    Ask (Size) 4.290 (400)
    Prev. Close 4.550
    Today's Range 4.090 - 4.620
    52wk Range 3.930 - 8.740
    Shares Outstanding 14,508,063
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY
    From Levi & Korsinsky, LLP
    Via ACCESS Newswire
    News headline image
    Kaplan Fox Class Action Reminder: Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Lead Plaintiff Deadline is November 2, 2026
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit

    Performance

    52-Week Range 51.7% below 52-week high
    4.220
    3.9352W Low 8.7452W High
    1 Week 12.3% below 1-week high
    4.091W Low 4.811W High

    Unicycive Therapeutics, Inc. - Common Stock (UNCY) traded between $3.93 and $8.74 over the past 52 weeks and last traded at $4.22, 51.7% below its 52-week high. Over the past week it ranged between $4.09 and $4.81.

    Past 12 Months
    -9.1%
    -18.7%
    -21.3%
    -36.3%
    -27.2%
    -8.7%
    1W -$0.42
    1M -$0.97
    3M -$1.14
    6M -$2.40
    YTD -$1.58
    1Y -$0.40

    UNCY was -8.7% over the past year, -36.3% over six months, -27.2% year to date, -9.1% in the last week.

    12 Months vs Market
    UNCY
    -8.7%
    DIA
    +9.9%
    SPY
    +15.0%
    QQQ
    +23.7%
    IWM
    +15.4%

    Over the past 12 months UNCY returned -8.7% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

    Volume & Liquidity 1.69× 3-mo avg
    Today 1,510,068 3-mo avg 895.8K
    1W
    1.3M
    1M
    931.3K
    3M
    895.8K
    6M
    1.1M
    YTD
    927.6K
    1Y
    798.4K

    UNCY most recently traded 1,510,068 shares against a 3-month average daily volume of 895.8K.

    More News

    Read More
    News headline image
    Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
    Via B2i Digital
    News headline image
    Kaplan Fox Shareholder Alert: Deadline to Lead in the Securities Fraud Lawsuit Against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is November 2, 2026
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
    Via B2i Digital
    News headline image
    Kaplan Fox Deadline Alert: Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors Have Until November 2, 2026 to Seek a Lead Plaintiff Role
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Deadline on November 2, 2026
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire
    News headline image
    Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action
    From Robbins LLP
    Via Business Wire
    News headline image
    Kaplan Fox Encourages Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to Contact the Firm Before Lead Plaintiff Deadline on November 2, 2026
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    Kaplan Fox Reminds Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to a Securities Class Action Deadline - Contact the Firm Before November 2, 2026
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility to Ensure it Resolved the FDA's Previously Noted Deficiencies
    Via Newsfile
    Topics Lawsuit
    News headline image
    UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire
    News headline image
    UNICYCIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Unicycive Therapeutics, Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    UNCY INVESTOR REMINDER: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role
    From Kirby McInerney LLP
    Via Business Wire
    News headline image
    Kaplan Fox Encourages Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to Contact the Firm to Learn About Their Legal Rights
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
    From Glancy Prongay Wolke & Rotter LLP
    Via Business Wire
    News headline image
    Law Offices of Frank R. Cruz Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders To Inquire About Securities Fraud Class Action
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    UNCY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    Deadline Approaching: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
    From Law Offices of Howard G. Smith
    Via Business Wire
    News headline image
    Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders to Contact the Firm for Information About Their Rights
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is Unicycive Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Unicycive Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Unicycive Therapeutics, Inc. - Common Stock trade on?
    Unicycive Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Unicycive Therapeutics, Inc. - Common Stock?
    The ticker symbol for Unicycive Therapeutics, Inc. - Common Stock is UNCY on the Nasdaq Stock Market
    What is the current price of Unicycive Therapeutics, Inc. - Common Stock?
    The current price of Unicycive Therapeutics, Inc. - Common Stock is 4.220
    When was Unicycive Therapeutics, Inc. - Common Stock last traded?
    The last trade of Unicycive Therapeutics, Inc. - Common Stock was at 10/02/26 04:00 PM ET
    What is the market capitalization of Unicycive Therapeutics, Inc. - Common Stock?
    The market capitalization of Unicycive Therapeutics, Inc. - Common Stock is 61.22M
    How many shares of Unicycive Therapeutics, Inc. - Common Stock are outstanding?
    Unicycive Therapeutics, Inc. - Common Stock has 61M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.